2020 American Transplant Congress
Conversion to Sirolimus to Prevent Recurrent Cytomegalovirus Infection/Disease: A Prospective and Randomized Trial
Hospital do Rim - UNIFESP, São Paulo, Brazil
*Purpose: Recurrent cytomegalovirus (CMV) infection occurs in 30-35% of kidney transplant recipients after completion of treatment and/or preemptive therapy. There is no consensus on the…2020 American Transplant Congress
Immuno-Modulation of Primed Xenogeneic T Cell Response by mTOR Blockade of T Cells and Porcine Endothelial Cells
Surgery, Duke University, Durham, NC
*Purpose: Porcine vascular endothelial cells (PECs) play a central role in xeno-recognition and costimulation. The objectives of this study were to characterize the immuno-phenotype of…2020 American Transplant Congress
Sirolimus Combined with Low-Dose Calcineurin Inhibitor in Kidney Transplant Recipients from Expanded Criteria Donors
Beijing Friendship Hospital, Capital Medical University, Beijing, China
*Purpose: To evaluate the efficacy and safety of conversion from calcineurin inhibitor-based immunosuppressive regimen to sirolimus combined with low-dose calcineurin inhibitor in recipients with abnormal…2020 American Transplant Congress
The Impact of Sirolimus on Weight Gain Post Heart Transplant
*Purpose: Obesity is common after heart transplant (HT), resulting in increased risk of new onset diabetes, all-cause and cardiovascular mortality and graft failure. Immunosuppressants (ISN)…2020 American Transplant Congress
Long Term Effect of Tacrolimus Conversion to Sirolimus with Prednisone-Free Regimen in Kidney Allograft Outcomes: A Dynamic Analysis of Graft Survival Using Joint Modeling
*Purpose: Findings on long-term impacts of the mammalian target of rapamycin inhibitor inhibitors on kidney allograft are scarce and mixed. A joint modeling approach can…2019 American Transplant Congress
Comparison of Initial Sirolimus (SRL) and Everolimus (EVR) Exposure Patterns in Kidney Transplant Recipients
Hospital do Rim, Nephrology Division, EPM - UNIFESP, São Paulo, Brazil
*Purpose: Despite distinct pharmacokinetic properties, SRL and EVR bind to the same intracellular target protein, suggesting that equivalent blood concentrations may exert similar pharmacodynamic effect.*Methods:…2019 American Transplant Congress
Slowed Progression of Maximal Intimal Thickening by Intravascular Ultrasound after Initiation of Sirolimus
1Children's Hospital Colorado, Aurora, CO, 2University of Florida Health, Gainesville, FL
*Purpose: Evidence in adult heart transplant (HT) patients (pt) shows that initiating sirolimus (SRL) slows progression of cardiac allograft vasculopathy (CAV) measured by intravascular ultrasound…2019 American Transplant Congress
Clinical Outcomes of Using mTOR Inhibitors with Reduced Dose of Calcineurin Inhibitors in Lung Transplant Recipients: A Single Center Experience
*Purpose: The use of mammalian target of rapamycin inhibitors (mTORi) in cardiothoracic transplantation has significantly increased over the past decade. Several recent clinical trials have…2019 American Transplant Congress
mTOR Inhibitors Associated with Higher Cardiovascular Adverse Events – A Large Population Database Analysis
*Purpose: Our study aimed to compare the adverse events (AEs) of tacrolimus to mammalian target of rapamycin (mTOR) inhibitors in solid organ transplant patients.*Methods: Our…2019 American Transplant Congress
Impact of Everolimus Therapy on HIV Persistence and Gene Expression in Transplant Patients
1UC San Francisco, San Francisco, CA, 2Case Western Reserve University, Cleveland, OH
*Purpose: mTOR is a key regulatory kinase that controls cell-cycle progression. mTOR inhibitors have been shown to reduce expression of CCR5 and promote viral transcriptional…
American Transplant Congress abstracts